# OnCo record lymphoma-bio-antigen-escape (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/lymphoma-bio-antigen-escape/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "lymphoma-bio-antigen-escape" ;
  schema:name "Antigen escape: how a lymphoma loses the thing the drug was aimed at"@en ;
  schema:alternateName "Antigen loss"@en, "CD19-negative relapse"@en, "CD20 loss"@en, "Target evasion"@en, "Epitope loss"@en ;
  schema:description "Treatments that find a cancer by one marker on its surface can be defeated if the cancer stops showing that marker. It is one of the main reasons an antibody or CAR-T treatment that worked stops working."@en ;
  schema:url <https://onco.cc/terms/lymphoma-bio-antigen-escape/> ;
  schema:dateModified "2026-09-30"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/2159-8290.CD-15-1020>, <https://doi.org/10.1182/blood-2008-08-175208>, <https://doi.org/10.1182/blood.2021010930> ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd22/>, <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/cd30/> ;
  onco:pathways <https://onco.cc/pathways/resistance-routes-map/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/> .